|Bid||14.19 x 900|
|Ask||14.20 x 900|
|Day's Range||14.00 - 14.30|
|52 Week Range||11.80 - 29.65|
|Beta (5Y Monthly)||1.13|
|PE Ratio (TTM)||49.17|
|Earnings Date||Aug 09, 2021 - Aug 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.63|
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned subsidiary, Enteris BioPharma, received a $10 million milestone payment from Cara Therapeutics (Nasdaq: CARA) related to the license agreement for the Peptelligence® oral formulation technology utilized in Oral KORSUVA™, the oral formulation of Cara's first-in-class KOR agonist, CR845/difelikefalin. Enteris i
A look at the shareholders of Cara Therapeutics, Inc. ( NASDAQ:CARA ) can tell us which group is most powerful...
The future of this troubled clinical-stage biotech rests on a single drug candidate that management hopes will treat an extremely common condition.